Betamethasone: Indication, Dosage, Side Effect, Precaution | MIMS Malaysia - Proper Use
Looking for:
Betamethasone dipropionate cream dosage. DESCRIPTION |
Betamethasone dipropionate cream dosage -
Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. In an open-label pediatric study of 43 evaluable patients, of the 10 subjects who showed evidence of suppression, 2 subjects were tested 2 weeks after discontinuation of betamethasone dipropionate cream, 0.
Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects. Patients using topical corticosteroids should receive the following information and instructions:. Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate.
It as positive in the in-vitro human lymphocyte chromosome aberration assay, and equivocal in the in-vivo mouse bone marrow micronucleus assay. This pattern of response is similar to that of dexamethasone and hydrocortisone. Reproductive studies with betamethasone dipropionate carried out in rabbits at doses of 1. These doses are approximately 0. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.
This dose is approximately 0. The abnormalities observed included umbilical hernias, cephalocele and cleft palates. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.
There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk.
Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are prescribed for a nursing woman. Use of betamethasone dipropionate cream, 0. The proportion of patients with adrenal suppression in this study was progressively greater, the younger the age group. Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.
Hypothalamic-pituitary-adrenal HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles, headaches and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen.
Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients. The following local adverse reactions are reported infrequently when betamethasone dipropionate cream USP, 0. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infections, skin atrophy, striae and miliaria.
Adverse reactions reported to be possibly or probably related to treatment with betamethasone dipropionate cream during a pedatric clinical study include signs of skin atrophy brusing, shininess. Apply a thin film of betamethasone dipropionate cream USP, 0. In some cases, twice-daily dosage may be necessary.
Rx only. Betamethasone dipropionate is the 17, dipropionate ester of betamethasone. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
There is a problem with information submitted for this request. Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID, plus expertise on managing health. To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you.
If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail.
You'll soon start receiving the latest Mayo Clinic health information you requested in your inbox. All rights reserved.
Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes. Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below. This site complies with the HONcode standard for trustworthy health information: verify here.
This content does not have an English version. This content does not have an Arabic version. See more conditions.
Products and services. Proper Use Drug information provided by: IBM Micromedex It is very important that you use this medicine only as directed by your doctor. Thank you for subscribing!
❾-50%}Betamethasone dipropionate cream dosage -
Dosage is individualised according to the disease being treated and patient response. Refer to the disease-specific product guidelines for detailed dosage recommendations. Child: As betamethasone Na phosphate and betamethasone acetate: Usual dose: 0.
Adult: For non-infected cases of the nose: As 0. Use the lowest effective dose for the shortest possible time. Discontinue if there is no clinical response within 7 days of treatment. Child: Same as adult dose. Adult: For short-term treatment of steroid-responsive cases: As 0. Adult: Dosage is individualised and adjusted according to the disease being treated, its severity and patient response.
As betamethasone Na phosphate: Usual dose: 0. Recommended regimens: Short-term treatment: mg daily for the 1st few days, then decrease by 0. Rheumatoid arthritis: 0. Other conditions: 1. Use the lowest effective dose. Adult: For non-infected cases: As 0. Adult: As betamethasone Na phosphate: mg via slow IV inj over 0. Use the minimum effective dose. Doses to be given via slow IV inj or infusion, may be repeated times in 24 hours as necessary depending on the condition being treated and patient response.
Adult: As 0. Re-evaluate treatment if condition worsens or does not improve within weeks. Dosage and treatment duration may vary according to the severity of the condition and patient response. Child: As 0. Adult: As betamethasone Na phosphate: mg as local inj into soft tissue lesions; may be repeated on 2 or 3 occasions according to patient response. Untreated systemic infections oral, parenteral ; idiopathic thrombocytopenic purpura IM ; perforated tympanic membrane otic.
Ophthalmic: Bacterial, fungal, viral, tuberculous or purulent eye infections; glaucoma, herpetic keratitis e. Topical: Untreated fungal, tubercular or bacterial skin infections; viral skin lesions e. Concomitant administration with live vaccines in patients receiving immunosuppressive doses. Special Precautions. Patient with history of local hypersensitivity to corticosteroids betamethasone valerate ; subjected to stress conditions e.
Avoid abrupt withdrawal particularly during prolonged therapy. Renal and hepatic impairment. Pregnancy and lactation. Adverse Reactions. Significant: Adrenal suppression e. Rarely, anaphylactoid reactions. Topical: Allergic contact dermatitis, systemic effects e.
Blood and lymphatic system disorders: Leucocytosis. Eye disorders: Papilloedema, corneal or scleral thinning, exacerbation of ophthalmic viral or fungal diseases; mydriasis, ptosis, epithelial punctate keratitis ophthalmic. Gastrointestinal disorders: Abdominal distension, dyspepsia, nausea, oesophageal ulceration, peptic ulcer with perforation and haemorrhage; acute pancreatitis; taste disturbance nasal. General disorders and administration site conditions: Malaise. Investigations: Weight gain.
Metabolism and nutrition disorders: Hypokalaemic alkalosis, impaired carbohydrate tolerance. Musculoskeletal and connective tissue disorders: Osteoporosis, tendon rupture, vertebral and long bone fractures, avascular osteonecrosis. Nervous system disorders: Headache. Psychiatric disorders: Irritability, mania, delusions, hallucinations, behavioural disturbances, anxiety, sleep disturbances, confusion. Reproductive system and breast disorders: Menstrual irregularity, amenorrhoea.
Respiratory, thoracic and mediastinal disorders: Nasal irritation and dryness, epistaxis, rebound congestion, bronchial asthma, perforation or ulceration of nasal septum, anosmia, parosmia, sneezing. Skin and subcutaneous tissue disorders: Atrophy, bruising, acne, telangiectasia, striae, hypertrichosis, Stevens-Johnson syndrome; pruritus, burning or stinging sensation, pain topical.
Vascular disorders: Thromboembolism. Patient Counseling Information. Ophthalmic: This drug may cause visual disturbances such as transient blurred vision; if affected, do not drive or operate machinery. Remove contact lenses prior to instillation of eye drops and wait at least 15 minutes before reinsertion. Monitoring Parameters. Monitor blood pressure, serum K and glucose, growth in children; signs and symptoms of infection, inj site reactions, HPA axis suppression, adrenal insufficiency.
Perform ophthalmic examination periodically. Drug Interactions. May reduce effects of anticholinesterases in patients with myasthenia gravis. Enhanced metabolism and decreased therapeutic effect with rifampicin, carbamazepine, phenobarbitone, phenytoin, primidone, aminoglutethimide, ephedrine. May antagonise the effects of hypoglycaemic agents e. May enhance the effect of coumarin anticoagulants.
Increased renal clearance of salicylates. Increased risk of hypokalaemia with theophylline, carbenoxolone, antifungals e. May reduce effect with mifepristone. May inhibit the growth promoting effects of somatropin. May increase the risk of tendon rupture with fluoroquinolones. May increase serum concentration with CYP3A4 inhibitors e. Potentially Fatal: May diminish the therapeutic effect of vaccines live or inactivated. Lab Interference. Description: Betamethasone is a corticosteroid with primarily glucocorticoid activity.
It induces phospholipase A 2 inhibitory proteins lipocortins and sequentially inhibits the release of arachidonic acid, thereby depressing the formation, release, and activity of prostaglandins, histamines, and other endogenous inflammatory chemical mediators. Pharmacokinetics: Absorption: Readily absorbed from the gastrointestinal tract oral ; absorbed percutaneously topical. Time to peak plasma concentration: minutes IV. This medicine is for use on the skin only. Do not get it in your eyes, mouth, or vagina.
Do not use it on skin areas that have cuts, scrapes, or burns. If it does get on these areas, rinse it off right away with water. This medicine should come with a patient information leaflet. Read and follow these instructions carefully. Ask your doctor if you have any questions.
This medicine should only be used for skin conditions that your doctor is treating. Check with your doctor before using it for other conditions, especially if you think that a skin infection may be present. This medicine should not be used to treat certain kinds of skin infections or conditions, such as severe burns. To help clear up your skin problem completely, it is very important that you keep using this medicine for the full time of treatment, even if your symptoms begin to clear up after a few days.
Do not miss any doses. Do not use the topical cream, gel, lotion, ointment, and spray on the face, scalp, groin, or underarms unless directed to do so by your doctor. Do not use on skin areas that may rub or touch together. The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing. There is a problem with information submitted for this request.
Betamethasone dipropionate cream contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has high corticosteroid activity and slight mineral-ocorticoid activity. Betamethasone dipropionate is the 17,dipropionate ester of betamethasone. Betamethasone dipropionate is a white to creamy white, odorless crystalline powder, insoluble in water. Each gram of betamethasone dipropionate cream 0. The corticosteroids are a class of compounds comprising steroid hormones, secreted by the adrenal cortex and their synthetic analogs.
Topical corticosteroids, such as betamethasone dipropionate, are effective in the treatment of corticosteroid-responsive dermatoses primarily because of their anti-inflammatory, antipruritic, and vasoconstrictive actions.
However, while the physiologic, pharmacologic, and clinical effects of the corticosteroids are well known, the exact mechanisms of their actions in each disease are uncertain. Betamethasone dipropionate, a corticosteroid, has been shown to have topical dermatologic and systemic pharmacologic and metabolic effects characteristic of this class of drugs. Topical corticosteroids can be absorbed from normal intact skin. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids.
Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Sixty-three pediatric patients ages 1 to 12 years, with atopic dermatitis, were enrolled in an open-label, hypothalamic-pituitary-adrenal HPA axis safety study. Studies performed with betamethasone dipropionate cream indicate that it is in the medium range of potency as compared with other topical corticosteroids. Betamethasone dipropionate cream is a medium-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older.
Betamethasone dipropionate cream is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.
Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary-free cortisol and ACTH stimulation tests.
If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug.
In an open-label pediatric study of 43 evaluable patients, of the 10 subjects who showed evidence of suppression, 2 subjects were tested 2 weeks after discontinuation of betamethasone dipropionate cream, 0. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. Information For Patients: This information is intended to aid in the safe and effective use of this medication.
It is not a disclosure of all possible adverse or intended effects. Patients using topical corticosteroids should receive the following information and instructions:. Carcinogenesis, Mutagenesis, Impairment Of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate. It was positive in the in-vitro human lymphocyte chromosome aberration assay, and equivocal in the in-vivo mouse bone marrow micronucleus assay.
This pattern of response is similar to that of dexamethasone and hydrocortisone. Reproductive studies with betamethasone dipropionate carried out in rabbits at doses of 1. These doses are approximately 0. Pregnancy: Teratogenic Effects: Pregnancy category C : Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.
Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0. This dose is approximately 0. The abnormalities observed included umbilical hernias, cephalocele and cleft palates.
Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant.
Nevertheless, caution should be exercised when topical corticosteroids are prescribed for a nursing woman. Pediatric Use: Use of betamethasone dipropionate cream, 0. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen.
Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.
Adverse reactions reported to be possibly or probably related to treatment with betamethasone dipropionate cream during a pediatric clinical study include signs of skin atrophy bruising, shininess. Apply a thin film of betamethasone dipropionate cream 0. In some cases, a twice-daily dosage may be necessary.
For Dermatologic Use Only 15 g 0. Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only.
Avoid contact with the eyes. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed. Patients should report any signs of local adverse reactions.
Other corticosteroid-containing products should not be used with betamethasone dipropionate cream without first talking to your physician. Laboratory Tests: The following tests may be helpful in evaluating HPA axis suppression: Urinary-free cortisol test ACTH stimulation test Carcinogenesis, Mutagenesis, Impairment Of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate.
Betamethasone dipropionate cream is not to be used with occlusive dressings. Distributed by: Actavis Pharma, Inc. Product Information. Inactive Ingredients. Marketing Information. Labeler - Actavis Pharma, Inc.
—12 mg (—2 mL)/dose at the appropriate site as follows: very large joint 1—2 mL; large joint 1 mL; medium joint —1 mL; small joint — mL. For. Dosage Forms & Strengths ; cream/lotion/ointment. % ; gel. % ; foam. % (Luxiq) ; spray. % (Sernivo). Dosage Forms & Strengths ; cream/lotion/ointment. % ; gel. % ; foam. % (Luxiq) ; spray. % (Sernivo). Apply a thin film of betamethasone dipropionate cream % to the affected skin areas once daily. In some cases, a twice-daily dosage may be necessary. Betamethasone Dipropionate % Rx ; Adults and Children: Apply thin film to affected area(s) 1–2 times daily. Do not occlude. ; Adverse Reactions. Increased risk of hypokalaemia with theophylline, carbenoxolone, antifungals e. The effects are not limited to systemic therapy; neonates, infants, and children may absorb proportionally larger amounts of topical corticosteroids than adults due to a larger skin surface area to body weight ratio, and therefore are more susceptible to developing systemic toxicity, especially with very-high-potency products. Chronic corticosteroid therapy e.This information is not country-specific. Please refer to the Malaysia prescribing information. Indications and Dosage. Intra-articular Osteoarthritis, Rheumatoid arthritis Adult: Adjunctive treatment for short term administration: As betamethasone Na phosphate and betamethasone acetate: mg 0. Adult: As betamethasone Na phosphate and betamethasone acetate: Usual dose: 0. Dosage is individualised according to the disease being treated and patient response. Refer to the disease-specific product guidelines for detailed dosage recommendations.
Child: As betamethasone Na phosphate and betamethasone acetate: Usual dose: 0. Adult: For non-infected cases of the nose: As 0.
Use the lowest effective dose for the shortest possible time. Discontinue if there is no clinical response within 7 days of treatment. Child: Same as adult dose. Adult: For short-term treatment of steroid-responsive cases: As 0. Adult: Dosage is individualised and adjusted according to the disease being treated, its severity and patient response.
As betamethasone Na phosphate: Usual dose: 0. Recommended regimens: Short-term treatment: mg daily for the 1st few days, then decrease by 0. Rheumatoid arthritis: 0. Other conditions: 1. Use the lowest effective dose. Adult: For non-infected cases: As 0. Adult: As betamethasone Na phosphate: mg via slow IV inj over 0. Use the minimum effective dose. Doses to be given via slow IV inj or infusion, may be repeated times in 24 hours as necessary depending on the condition being treated and patient response.
Adult: As 0. Re-evaluate treatment if condition worsens or does not improve within weeks. Dosage and treatment duration may vary according to the severity of the condition and patient response. Child: As 0. Adult: As betamethasone Na phosphate: mg as local inj into soft tissue lesions; may be repeated on 2 or 3 occasions according to patient response. Untreated systemic infections oral, parenteral ; idiopathic thrombocytopenic purpura IM ; perforated tympanic membrane otic.
Ophthalmic: Bacterial, fungal, viral, tuberculous or purulent eye infections; glaucoma, herpetic keratitis e. Topical: Untreated fungal, tubercular or bacterial skin infections; viral skin lesions e. Concomitant administration with live vaccines in patients receiving immunosuppressive doses. Special Precautions. Patient with history of local hypersensitivity to corticosteroids betamethasone valerate ; subjected to stress conditions e.
Avoid abrupt withdrawal particularly during prolonged therapy. Renal and hepatic impairment. Pregnancy and lactation. Adverse Reactions. Significant: Adrenal suppression e.
Rarely, anaphylactoid reactions. Topical: Allergic contact dermatitis, systemic effects e. Blood and lymphatic system disorders: Leucocytosis. Eye disorders: Papilloedema, corneal or scleral thinning, exacerbation of ophthalmic viral or fungal diseases; mydriasis, ptosis, epithelial punctate keratitis ophthalmic. Gastrointestinal disorders: Abdominal distension, dyspepsia, nausea, oesophageal ulceration, peptic ulcer with perforation and haemorrhage; acute pancreatitis; taste disturbance nasal.
General disorders and administration site conditions: Malaise. Investigations: Weight gain. Metabolism and nutrition disorders: Hypokalaemic alkalosis, impaired carbohydrate tolerance. Musculoskeletal and connective tissue disorders: Osteoporosis, tendon rupture, vertebral and long bone fractures, avascular osteonecrosis. Nervous system disorders: Headache. Psychiatric disorders: Irritability, mania, delusions, hallucinations, behavioural disturbances, anxiety, sleep disturbances, confusion.
Reproductive system and breast disorders: Menstrual irregularity, amenorrhoea. Respiratory, thoracic and mediastinal disorders: Nasal irritation and dryness, epistaxis, rebound congestion, bronchial asthma, perforation or ulceration of nasal septum, anosmia, parosmia, sneezing. Skin and subcutaneous tissue disorders: Atrophy, bruising, acne, telangiectasia, striae, hypertrichosis, Stevens-Johnson syndrome; pruritus, burning or stinging sensation, pain topical.
Vascular disorders: Thromboembolism. Patient Counseling Information. Ophthalmic: This drug may cause visual disturbances such as transient blurred vision; if affected, do not drive or operate machinery. Remove contact lenses prior to instillation of eye drops and wait at least 15 minutes before reinsertion. Monitoring Parameters. Monitor blood pressure, serum K and glucose, growth in children; signs and symptoms of infection, inj site reactions, HPA axis suppression, adrenal insufficiency.
Perform ophthalmic examination periodically. Drug Interactions. May reduce effects of anticholinesterases in patients with myasthenia gravis. Enhanced metabolism and decreased therapeutic effect with rifampicin, carbamazepine, phenobarbitone, phenytoin, primidone, aminoglutethimide, ephedrine.
May antagonise the effects of hypoglycaemic agents e. May enhance the effect of coumarin anticoagulants. Increased renal clearance of salicylates. Increased risk of hypokalaemia with theophylline, carbenoxolone, antifungals e. May reduce effect with mifepristone. May inhibit the growth promoting effects of somatropin. May increase the risk of tendon rupture with fluoroquinolones. May increase serum concentration with CYP3A4 inhibitors e. Potentially Fatal: May diminish the therapeutic effect of vaccines live or inactivated.
Lab Interference. Description: Betamethasone is a corticosteroid with primarily glucocorticoid activity. It induces phospholipase A 2 inhibitory proteins lipocortins and sequentially inhibits the release of arachidonic acid, thereby depressing the formation, release, and activity of prostaglandins, histamines, and other endogenous inflammatory chemical mediators. Pharmacokinetics: Absorption: Readily absorbed from the gastrointestinal tract oral ; absorbed percutaneously topical.
Time to peak plasma concentration: minutes IV. Distribution: Crosses the placenta and enters breast milk. Metabolism: Metabolised primarily in the liver. Elimination half-life: 6. Chemical Structure. PubChem Database. Protect from light and moisture. Protect from light. Do not freeze. Protect from extreme heat exposure. MIMS Class. ATC Classification. S01BA06 - betamethasone ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye. S02BA07 - betamethasone ; Belongs to the class of corticosteroids used in the treatment of inflammation of the ear.
S03BA03 - betamethasone ; Belongs to the class of corticosteroids used in ophthalmologic and otologic preparations. R01AD06 - betamethasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis. Used in the treatment of dermatological diseases. H02AB01 - betamethasone ; Belongs to the class of glucocorticoids.
Used in systemic corticosteroid preparations. Betamethasone Systemic. Lexicomp Online. Hudson, Ohio.
Comments
Post a Comment